Monte Rosa Therapeutics, Inc. (GLUE)
| Market Cap | 1.07B +175.0% |
| Revenue (ttm) | 28.73M -83.9% |
| Net Income | -161.12M |
| EPS | -1.75 |
| Shares Out | 85.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,212,917 |
| Open | 12.35 |
| Previous Close | 12.26 |
| Day's Range | 12.21 - 12.73 |
| 52-Week Range | 6.23 - 25.77 |
| Beta | 1.50 |
| Analysts | Strong Buy |
| Price Target | 28.50 (+126.19%) |
| Est. Earnings | Nov 5, 2026 |
About GLUE
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1α, IL-1β and IL... [Read more]
Financial Performance
In 2025, Monte Rosa Therapeutics's revenue was $123.67 million, an increase of 63.54% compared to the previous year's $75.62 million. Losses were -$38.63 million, -46.87% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for GLUE stock is "Strong Buy." The 12-month stock price target is $28.5, which is an increase of 126.19% from the latest price.
News
Monte Rosa Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is advancing a pipeline of molecular glue degraders, with three clinical assets and a focus on NEK7 for ASCVD, gout, and HS. Strategic partnerships, notably with Novartis for MRT-6160, support rapid development in autoimmune indications. Cash runway extends into 2029, enabling progress across all key programs.
Monte Rosa Therapeutics to receive $50M milestone payment from Novartis
Monte Rosa Therapeutics (GLUE) announced that its collaborator Novartis (NVS) has initiated a Phase 2 clinical study for the VAV1-directed MGD MRT-6160 in people living with Sjogren’s disease. This st...
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Phase 2 study to be conducted in participants with Sjögren's disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to ...
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today an...
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today an...
Monte Rosa Therapeutics doses first patient in MODeFIRe-1 trial
Monte Rosa Therapeutics (GLUE) announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 study evaluating MRT-2359 in combination with apalutamide, a second-generation androgen receptor...
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Monte Rosa FPD in MODeFIRe-1, a P2 Study of MRT-2359 in Combo w/ Apalutamide in Patients w/ AR Mutation-Positive Metastatic Castration-Resistant Cancer
Monte Rosa Therapeutics price target lowered to $28 from $35 at Guggenheim
Guggenheim lowered the firm’s price target on Monte Rosa Therapeutics (GLUE) to $28 from $35 and keeps a Buy rating on the shares after updating the firm’s model to reflect…
Monte Rosa Therapeutics reports Q2 revenue $8.97M, consensus $12.88M
“We’re tremendously proud of our progress to date in 2026, defined by strong execution across our clinical-stage portfolio, with two Phase 2 trials activated and additional trials expected across our…
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to initiate multiple MRT-8102...
Monte Rosa Therapeutics Quarterly report: Q2 2026
Monte Rosa Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Monte Rosa Therapeutics Earnings release: Q2 2026
Monte Rosa Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Monte Rosa Therapeutics Slides: Corporate presentation
Monte Rosa Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Monte Rosa Therapeutics price target lowered to $27 from $37 at Wedbush
Wedbush analyst Robert Driscoll lowered the firm’s price target on Monte Rosa Therapeutics (GLUE) to $27 from $37 and keeps an Outperform rating on the shares. The firm notes competitor…
Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback
Monte Rosa Therapeutics (GLUE) is trading lower after Novo Nordisk’s (NVO) ZEUS trial failed to show a cardiovascular benefit for IL 6 inhibition, a readout that dampens sentiment around inflammation…
Monte Rosa Therapeutics price target lowered at Jefferies after Novo trial miss
Jefferies lowered the firm’s price target on Monte Rosa Therapeutics (GLUE) to $25 from $40 and keeps a Buy rating on the shares after Novo Nordisk’s (NVO) ZEUS study of…
Monte Rosa Therapeutics price target raised to $40 from $30 at Jefferies
Jefferies raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $40 from $30 and keeps a Buy rating on the shares. Topline data for Novo Nordisk’s (NVO) ZEUS…
Monte Rosa Therapeutics price target raised, named a ‘top pick’ at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $35 from $30 and keeps a Buy rating on the shares, which the analyst is…
Monte Rosa Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company presented updates on its molecular glue degrader pipeline, highlighting strong CRP reduction in cardiovascular risk patients, promising prostate cancer data, and upcoming phase II studies in ASCVD, gout, and HS. Strategic partnerships and significant interest position the company for further growth.
Monte Rosa Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
The conference highlighted progress in molecular glue degraders for oncology and inflammation, with MRT-2359 advancing to phase II in AR mutant prostate cancer and NEK7 degrader MRT-8102 showing strong CRP reduction. Multiple new trials and INDs are planned across the pipeline.
Monte Rosa Therapeutics price target raised to $31 from $30 at JPMorgan
JPMorgan analyst Brian Cheng raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $31 from $30 and keeps an Overweight rating on the shares.
Monte Rosa Therapeutics reports Q1 revenue $4.21M, consensus $11.39M
“We continue to make excellent progress advancing multiple programs through the clinic, with all three of our clinical-stage programs approaching Phase 2 trial initiations,” said Markus Warmuth, Chief...
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with ele...
Monte Rosa Therapeutics Earnings release: Q1 2026
Monte Rosa Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Monte Rosa Therapeutics Quarterly report: Q1 2026
Monte Rosa Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.